According to a study published by Insure Insights, the global liposomal doxorubicin market is estimated to grow at a CAGR of 6.5% during the forecast period. Liposomal doxorubicin is drug used to treat cancer. It contains the chemotherapy drug doxorubicin enveloped in a fatty covering called a liposome. It is used in the treatment for various types of cancer, such as breast cancer, multiple myeloma, ovarian cancer, and others. Liposomal doxorubicin is a light red liquid that is administered through a drip (infusion) into bloodstream. Doxorubicin is an anthracycline that works by blocking an enzyme called topo isomerase 2 that cancer cells utilizes in order to divide and grow. Liposomal doxorubicin is doxorubicin contained in small spheres known as pegylated liposomes. These spheres sustain the doxorubicin in the bloodstream longer, so that more of the drug acts on the cancer cells.

Top Driver: The Rising Prevalence of Cancer Cases Across the World and Rise in Research and Development Activities

The rising prevalence of cancer cases across the world is one of the major factors driving the growth of the global liposomal doxorubicin market. In addition, the sedentary lifestyle and unhealthy eating habits leading to several health issues are considered as significant factors that are likely to drive the market during the forecast period. The rise in research and development activities are estimated to create lucrative growth opportunities for the market players in the coming years. Moreover, the development of the healthcare infrastructure is expected to propel the market growth in the coming future.

Breast Cancer Segment is Estimated to Witness Significant Growth During the Forecast Period

The liposomal doxorubicin market has been segmented into Kaposi sarcoma, leukemia, breast cancer, and others by the application. Among these, breast cancer accounted for the highest market share, due to surging demand for the treatment in increasing breast cancer cases across the world. According to Breastcancer.org, about 1 in 8 U.S. women develop invasive breast cancer throughout their lifetime. In 2019, approximately 268,600 new cases of invasive breast cancer were estimated to be diagnosed in women in the U.S., along with 62,930 new non-invasive breast cancer cases. On the basis of product type, the market is segmented into Doxil/Caelyx, Lipodox, Myocet, and Others

The Increasing Prevalence of Cancer and The Presence of Advanced Healthcare Infrastructure to Benefit North America Market

North America holds the largest market share in the global liposomal doxorubicin market. The growth is attributed to the increasing prevalence of sarcomas and ovarian, breast, and liver cancers, as well as several other cancers. In addition to this, the presence of advanced healthcare infrastructure and facilities and high patient awareness levels concerning the various available treatments are key factors stimulating the growth in this region. The substantial reimbursement and regulatory framework are also other significant factors driving the global liposomal doxorubicin. Following North America, the Asia Pacific region is expected to witness significant growth during the forecast period. The factors driving the growth of the market include enlarging patient pool, growing investment by the private & public players, and rising awareness of efficacious drug alternatives.

Players to Focus on Drug Development

The global liposomal doxorubicin market is estimated to stay fragmented during the forecast period owing to the possible new entrants. The major market players operating in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson, Bristol Myers Squibb Company, GlaxoSmithKline Plc., and SkyePharma Inc.

Celsion Corporation: In January 2019, Celsion Corporation, an oncology drug development company, declared results from Phase I TARDOX trial of ThermoDox conducted at the University of Oxford, United Kingdom. The TARDOX trial evaluated the safety and efficacy of ThermoDox, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.

Scope of the Report

By Application  

• Kaposi sarcoma
• Leukemia
• Breast cancer
• Others

By Product Type  

• Doxil/Caelyx
• Lipodox
• Myocet
• Others

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.